HaffnerSMLehtoSRonnemaaTPyöräläKLaaksoM.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med1998; 339:229–234.
2.
GrundySMCleemanJIMerzCNBrewerHBJrClarkLTHunninghakeDBImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation2004; 110:227–239.
3.
MurrayCJLopezAD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.Lancet1997; 349:1498–1504.
4.
BrunzellJDDavidsonMFurbergCDGoldbergRBHowardBVSteinJHWitztumJL. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.J Am Coll Cardiol2008; 51:1512–1524.
5.
StamlerJWentworthDNeatonJD.Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA1986; 256:2823–2828.
6.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344:1383–1389.
7.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med1998; 339:1349–1357.
8.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002; 360:7–22.
9.
DownsJRClearfieldMWeisSWhitneyEShapiroDRBeerePAPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFcaps/Texcaps. AirForce/Texas Coronary Atherosclerosis Prevention Study. JAMA1998; 279:1615–1622.
10.
SacksFMPfefferMAMoyeLARouleauJLRutherfordJDColeTGThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med1996; 335:1001–1009.
11.
ShepherdJCobbeSMFordIIslesCGLorimerARMacFarlanePWPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med1995; 333:1301–1307.
12.
RidkerPMDanielsonEFonsecaFAGenestJGottoAMJrKasteleinJJRosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med2008; 359:2195–2207.
13.
CollinsRArmitageJParishSSleighPPetoR. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.Lancet2003; 361:2005–2016.
14.
ColhounHMBetteridgeDJDurringtonPNHitmanGANeilHALivingstoneSJPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004; 364:685–696.
15.
KearneyPMBlackwellLCollinsRKeechASimesJPetoREfficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet2008; 371:117–125.
16.
RydenLStandlEBartnikMVan den BergheGBetteridgeJde BoerMJGuidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J2007; 28:88–136.
17.
LibbyP. The forgotten majority: unfinished business in cardiovascular risk reduction.J Am Coll Cardiol2005; 46:1225–1228.
18.
NichollsSJTuzcuEMKalidindiSWolskiKMoonKWSipahiIEffect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol2008; 52:255–262.
19.
StaelsBMaesMZambonA. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.Nat Clin Pract Cardiovasc Med2008; 5:542–553.
20.
FrickMHEloOHaapaKHeinonenODHeinsalmiPHeloPHelsinki Heart Study: primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med1987; 317:1237–1245.
21.
RubinsHBRobinsSJCollinsDFyeCLAndersonJWElamMBGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med1999; 341:410–418.
22.
ManninenVEloMOFrickMHHaapaKHeinonenOPHeinsalmiPLipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA1988; 260:641–651.
23.
RobinsSJCollinsDWittesJTPapademetriouVDeedwaniaPCSchaeferEJRelation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA2001; 285:1585–1591.
24.
RyeKABarterPJ. Formation and metabolism of prebeta-migrating, lipidpoor apolipoprotein A-I.Arterioscler Thromb Vasc Biol2004; 24:421–428.
25.
ManninenVTenkanenLKoskinenPHuttunenJKManttariMHeinonenOPFrickMH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.Circulation1992; 85:37–45.
26.
RobinsSJ. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?Curr Opin Lipidol2003; 14:575–583.
27.
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet2001; 357:905–910.
28.
KeechASimesRJBarterPBestJScottRTaskinenMREffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet2005; 366:1849–1861.
29.
BuseJBBiggerJTByingtonRPCooperLSCushmanWCFriedewaldWTAction to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol2007; 99:21i–33i.
30.
MazzoneTMeyerPMFeinsteinSBDavidsonMHKondosGTD'AgostinoRBSrEffect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA2006; 296:2572–2581.
31.
NissenSENichollsSJWolskiKNestoRKupferSPerezAComparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA2008; 299:1561–1573.
32.
DavidsonMMeyerPMHaffnerSFeinsteinSD'AgostinoRSrKondosGTIncreased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation2008; 117:2123–2130.
33.
DormandyJACharbonnelBEcklandDJErdmannEMassi-BenedettiMMoulesIKSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet2005; 366:1279–1289.
34.
LincoffAMWolskiKNichollsSJNissenSE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.JAMA2007; 298:1180–1188.
35.
NissenSEWolskiK. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med2007; 356:2457–2471.
36.
HomePDPocockSJBeck-NielsenHCurtisPSGomisRHanefeldMRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet2009; 373:2125–2135.
37.
Clofibrate and niacin in coronary heart disease. JAMA1975; 231:360–381.
38.
TaylorAJLeeHJSullenbergerLE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3.Curr Med Res Opin2006; 22:2243–2250.
39.
TaylorAJSullenbergerLELeeHJLeeJKGraceKA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.Circulation2004; 110:3512–3517.
40.
TaylorAJVillinesTCStanekEJDevinePJGriffenLMillerMExtended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med2009; 361:2113–2122.
41.
BrownBGZhaoXQChaitAFisherLDCheungMCMorseJSSimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med2001; 345:1583–1592.
42.
LeeJMRobsonMDYuLMShirodariaCCCunningtonCKylintireasIEffects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol2009; 54:1787–1794.
43.
HarrisWSMillerMTigheAPDavidsonMHSchaeferEJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives.Atherosclerosis2008; 197:12–24.
44.
BarterPJ. Hugh Sinclair Lecture: the regulation and remodelling of HDL by plasma factors.Atheroscler Suppl2002; 3:39–47.
45.
BarterPJ. CETP and atherosclerosis.Arterioscler Thromb Vasc Biol2000; 20:2029–2031.
46.
BarterPJChapmanMJHennekensCHRaderDJTallAR. Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis.Arterioscler Thromb Vasc Biol2003; 23:160–167.
47.
BrousseauMESchaeferEJWolfeMLBloedonLTDigenioAGClarkRWEffects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med2004; 350:1505–1515.
48.
OkamotoHYonemoriFWakitaniKMinowaTMaedaKShinkaiH. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.Nature2000; 406:203–207.
49.
RittershausCWMillerDPThomasLJPicardMDHonanCMEmmettCDVaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol2000; 20:2106–2112.
50.
BarterPJCaulfieldMErikssonMGrundySMKasteleinJJKomajdaMEffects of torcetrapib in patients at high risk for coronary events. N Engl J Med2007; 357:2109–2122.
51.
BotsMLVisserenFLEvansGWRileyWARevkinJHTegelerCHTorcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet2007; 370:153–160.
52.
KasteleinJJvan LeuvenSIBurgessLEvansGWKuivenhovenJABarterPJEffect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med2007; 356:1620–1630.
53.
NissenSETardifJCNichollsSJRevkinJHShearCLDugganWTEffect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med2007; 356:1304–1316.
54.
ForrestMJBloomfieldDBriscoeRJBrownPNCumiskeyAMEhrhartJTorcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol2008; 154:1465–1473.
BallantyneCMHoogeveenRCBangHCoreshJFolsomARHeissGSharrettAR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middleaged men and women in the Atherosclerosis Risk in Communities (ARIC) study.Circulation2004; 109:837–842.
57.
SerruysPWGarcia-GarciaHMBuszmanPErnePVerheyeSAschermannMEffects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation2008; 118:1172–1182.
58.
RosensonRSHislopCMcConnellDElliottMStasivYWangNWatersDD. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.Lancet2009; 373:649–658.
